In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America

Abstract

We compared the in vitro activity of BMS-207147, an investigational triazole, with those of itraconazole and fluconazole against 613 clinical bloodstream isolates of Candida spp. collected from SENTRY participating hospitals during 1997 and 1998. Overall, BMS-207147 was the most active azole against all Candidaspp. While both BMS-207147 and itraconazole displayed a stepwise decrease in activity against isolates for which the fluconazole MICs were elevated, BMS-207147 had two- to fourfold greater activity than itraconazole both against Candida spp. that were dose-dependently fluconazole susceptible and against those that were fluconazole resistant.

Madurella mycetomatis Is Highly Susceptible to Ravuconazole

“…Ravuconazole is a broad-spectrum triazole that showed activity against a wide array of fungal species including Aspergillus spp., Candida spp., and Cryptococcus neoformans [9], [10]. Studies have shown that the efficacy of this new triazole was comparable to that of posaconazole and voriconazole [9], [10], [11]. In addition to antifungal activity, ravuconazole also showed in vitro activity against the parasite Trypanosoma cruzi, the causative agent of Chagas disease, another neglected tropical disease on the WHO list [12].…”

Clinical consequences of resistant Candida infections in intensive care

“…Major Fairchild et al [8] Nolla-Salas et al [9] Saiman et al [10] Swoboda et al [11] Tortorano et al [12] Trick et al [2] Period studied 1992-1998 1993-1995 1991-1998 1991-1992 1993-1995 1990-2002 1983-2002 1989-1999 [19,20]. In this programme, the authors also demonstrated large variations within the same country.…”

“…Tortorano et al collected all Candida infections in the medicosurgical ICU in one hospital [12]. Among the 58 strains tested, all C. albicans strains (n = 19) were susceptible to all of the drugs evaluated. Among the C. glabrata strains (n = 39), the authors reported an increase in the MIC of fluconazole from 1 g/mL to 32 g/mL during treatment with 400 mg/day for 10 days in one patient.…”

Investigational Antifungal Agents

“…All of the new triazoles have excellent in vitro activity against a wide variety of fungal pathogens ( Table 1). [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] provide similar evidence that these agents will be effective. 17,18 In vitro studies indicate that the agents also may be effective in treating infections caused by Cryptococcus sp.…”